Co-Located Conference AgendasAntibodies and Antibody Drug Conjugates | Drug Discovery India 2016 | 
Thursday, 29 September 2016 |
Draft Agenda- Subject to Change |
| | 08:00 | Registration | 09:00 | Inauguration | 09:20 |  | Keynote Presentation Welcome Address
Rathnam Chaguturu, CEO, Innovation Czar-iDDPartners, United States of America
|
| 09:40 | | |
Session I: Emerging Trends in Antibody Drug Conjugates |
| | 10:10 | Coffee Break and Networking in the Exhibition Area | 10:40 | Antibody Drug Conjugates- Current Status & Future Prospects
Sanjay Bajaj, Managing Director, Select Biosciences India Pvt Ltd, India
| 11:10 |  Antibody Drug Conjugates: Highroad of New Technologies
Priyaranjan Pattanaik, Associate Research Director, Syngene International Ltd
| |
Session II: ADC for Cancer Treatment |
| | 11:55 | ADC - A Magic Bullet to Cancer Therapy
Lavleen Kumar Gupta, Director, IgY Immunologix India Pvt Ltd, India
| 12:40 |  | Keynote Presentation Antibody-Drug Conjugates for Hematological Malignancies
Andrew Polson, Principal Scientist, Genentech, United States of America
|
| 13:40 | Lunch Break and Networking in the Exhibition Area | |
Session III: Advances in Antibody and ADC-I |
| | 14:40 | Cell Line Engineering Approaches towards Quantity and Quality Improvement of Recombinant mAb
Sanjeev Gupta, General Manager -Advanced Biotech Lab, Ipca Laboratories Ltd., India
| 15:25 | Antibody Drug Conjugates beyond Cancer Therapeutics
Pazhanimuthu Annamalai , Managing Director, AURA Biotechnologies Private Limited, India
| 16:10 | Coffee Break and Networking in the Exhibition Area | |
Session IV: Advances in Antibody and ADC-II |
| | 16:40 | Monoclonal Antibody and Drug combination Therapy for an Effective Treatment of Type I Diabetes
T Mahesh, Research Scholar, JSS College of Pharmacy, India
| 17:10 | Title to be Finalized
Jens Lohrmann, Senior Global Program Manager- Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Switzerland
| 17:55 | End of Day 1 of Conference |
Friday, 30 September 201609:30 | | 10:15 | Coffee Break and Networking in the Exhibition Area | |
Session V: Advances in Development & Analysis of ADCs |
| | 10:45 | Plenary Talk: Antibody based Radiopharmaceuticals for Diagnosis and Therapy
Mythili Kameswaran, Scientific Officer "G", Bhabha Atomic Research Centre , India
| 11:45 | Best Practices in Developing Bioanalytical Assays for Assessment of Antibody-Drug Conjugates
Arumugam Muruganandam, Mananging Director & Chief Scientific Officer, Affigenix Biosolutions Pvt Ltd, India
| 12:30 | ADCs : Analytical Approaches
Rajgopal Rudrarapu, Research Associate, Aurobindo Pharma, India
| 13:00 | Poster Viewing | 13:15 | Lunch Break and Networking in the Exhibition Area | |
Session VI: Novel Approaches in ADC |
| | 14:15 | | 15:15 | Development of Robust, Scalable Site-Specific Conjugation for Monoclonal and Bispecific mAbs: A DOE Approach
Sanjay Nilapwar, Scientist (Development- ADC), MedImmune, United States of America
| 16:00 | Coffee Break and Networking in the Exhibition Area | 16:30 | Panel Discussion: Drug Discovery and ADC- An Industry Perspective
Moderator:
V N Balaji, Discovery Research Advisor, India
Panelists:
Andrew Polson, Principal Scientist, Genentech, USA
Monideepa Roy, Director- Research & Development, Invictus Oncology Pvt Ltd, India
Subrahmanyam Vangala, CEO, InCan Solutions Pvt Ltd, Canada
Susanta Samajdar, Vice President - Med Chem, Aurigene Technologies, India | 17:20 | End of Conference |
|
Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonAntibodies and Antibody Drug ConjugatesAntibodies and Antibody Drug Conjugates in BengaluruBengaluruSELECTBIOenquiries@selectbiosciences.com
